List view / Grid view
Mayo Clinic researchers have created the world’s first biobank of human salivary gland tissue-organoids, offering a resource for developing regenerative therapies to treat chronic dry mouth.
Cytokine release syndrome (CRS) is a major barrier in cancer immunotherapy - but what if we could prevent it before it begins? Dr Liam Tremble, Principal Scientist at Poolbeg Pharma, discusses how POLB 001, an oral anti-inflammatory candidate, could offer a new way forward.
Researchers have developed the first fully stem cell-derived model of human ovarian organoids, or "ovaroids," offering a powerful new tool for studying infertility, differences in sex development (DSDs), and related reproductive disorders.
Tyra Biosciences has announced new data showing that its investigational therapy, TYRA-300, improves bone growth and corrects skeletal abnormalities in preclinical models of achondroplasia and hypochondroplasia.
ELRIG has announced the keynote speakers for Drug Discovery 2025, its flagship life sciences event taking place in Liverpool, England this October.
Vitalant is transforming the path from preclinical drug discovery to patient care by enabling access to cutting-edge cell and gene therapies. With decades of expertise and a nationwide network, find out how they bridge the gap between innovative treatments and local communities, ensuring life-changing therapies reach patients efficiently.
Scenic Biotech and Stanford University have published a study identifying PLA2G15 as a new drug target in neurodegenerative and metabolic diseases, potentially enabling future treatments for conditions like Niemann-Pick type C.
The body undergoes changes with age that can lead to conditions like sarcopenia and osteoarthritis, burdening individuals and healthcare systems. Find out how Rejuvenate Biomed uses AI to decode ageing biology and develop combination therapies targeting the root causes of age-related diseases, offering hope for better treatments and quality of…
K Navigator, a new AI-powered research co-pilot, is set to transform biomedical science by helping researchers explore complex data and accelerate discoveries.
Scientists have developed a new drug, SHP1705, that targets hijacked circadian clock proteins used by glioblastoma stem cells to grow and resist treatment.
CatalYm announces new preclinical data showing that its clinical-stage antibody, visugromab, can overcome resistance to antibody-drug conjugates (ADCs), showing potential to restore anti-tumour immune responses in solid tumours.
Enedra Therapeutics has secured new funding to advance its AI-driven CASPAROV platform, aimed at developing therapies for difficult-to-treat cancers
AI is reshaping drug discovery – but not without resistance. In this two-part conversation, André França and Eli Pollock share honest insights about the real barriers to AI adoption in life sciences and how embedding domain expertise into AI workflows might be the key to unlocking its full potential.
Metrion Biosciences has introduced a breakthrough NaV1.9 screening assay, aimed at overcoming historical challenges in pain research and advancing the development of non-opioid treatments.
Cell and gene therapy is rapidly transforming the treatment of complex diseases, yet scaling production efficiently remains a challenge. Dr Tia Harmon from PHC Corporation of North America explores the innovations that are optimising cell expansion to enhance the discovery of advanced therapies.
